1. ROLE OF RADIATION IN SMALL CELL
LUNG CANCER
Dr Bharti Devnani
Moderator:- Dr Sheh Rawat
2. Staging of SCLC depends on radiation portals
(Veteran’s administration lung group)
Limited Stage
Disease confined to I/L hemithorax which could be
safely encompassed with in a tolerable RT field.
T1, T2, nonmetastatic
Contralateral mediastinal and I/L SCF
Extensive stage
Beyond I/L hemithorax
T3,T4 and metastatic disease
3. Definitive (For LS)
Thoracic radiation as a part of CCRT
Adjuvant RT
Node positive cases after lobectomy
Prophylactic cranial irradiation
Palliative EXRT
Thoracic
Brain mets
Bone mets
Oncologic emergencies
SVCO
Spinal cord compression
Palliative brachytherapy
Endobronchial brachytherapy: Hemoptysis
5. EVOLUTION
Before the introduction of chemo in 1970,
RT was the mainstay of treatment
CT
More local recurrences with chemo alone
CT+RT-Standarad of care
6. EVIDENCE FOR THORACIC RADIOTHERAPY
25-30% reduction in the local recurrence with 5-7% increase in 2 year survival
with addition of radiotherapy
Pignon et al NEJM 1992 327;1618-24
7. ISSUES IN THORACIC RT OF SCLC
Sequencing with chemotherapy
(concurrent v/s sequential)
Timing of RT
(Early v/s late)
Portals
(before chemotherapy v/s shrinking field)
Dose and fractionation schedules
(conventional v/s hyperfractionation)
8. ISSUES IN THORACIC RT OF SCLC
Sequencing with chemotherapy
(concurrent v/s sequential)
Timing of RT
(Early v/s late)
Portals
(before chemotherapy v/s shrinking field)
Dose and fractionation schedules
(conventional v/s hyperfractionation)
9. Takada et al.J Clin Oncol 2002; 20:3054-60.
Better outcome with CCT with a trend towards improved OS.
Concurrent RT reduces the risk of tumor repopulation and
development of resistant clones.
Radiosensitizing effect
10. ISSUES IN THORACIC RT OF SCLC
Sequencing with chemotherapy
(concurrent v/s sequential)
Timing of RT
(Early v/s late)
Portals
(before chemotherapy v/s shrinking field)
Dose and fractionation schedules
(conventional v/s hyperfractionation)
11. Benefit in 2 year survival rate with early RT(within 9 weeks or before 3rd cycle)
12. Factors which have significant impact on the benefit
of early RT were:-
Type of chemotherapy
The fractionation scheme
14. Cancer Treat Rev 2007; 33:461-73.
Significant 2 & 5 years improvement in survival when
RT was started within 30 days of platinum based chemo
(2-year survival: HR: 0.73, 5-year survival: HR: 0.65).
This was even more pronounced when the overall
treatment time of chest radiotherapy was less than 30
days.
15. Early and concurrent chemoradiation is preferred over
late and sequential schedule.
16. ISSUES IN THORACIC RT OF SCLC
Sequencing with chemotherapy
(concurrent v/s sequential)
Timing of RT
(Early v/s late)
Dose and fractionation schedules
(conventional v/s hyperfractionation)
Portals
(before chemotherapy v/s shrinking field)
17. High chances of local recurrence with conventional
RT, attempts made to improve the outcome by:-
Hyperfractionated
Accelerated
radiotherapy
Dose escalation
20. ISSUES IN THORACIC RT OF SCLC
Sequencing with chemotherapy
(concurrent v/s sequential)
Timing of RT
(Early v/s late)
Dose and fractionation schedules
(conventional v/s hyperfractionation)
Portals
(before chemotherapy v/s shrinking field)
21. RT PORTALS
PET based planning should be used. (PET at the
time of radiotherapy planning or within 4 weeks)
GTV = Post induction chemotherapy volume
Omission of elective nodal irradition.
Low rates of local recurrence(11% with only CT
based planning, 3 % with PET based planning)
Decreases the esophageal toxicity significantly.
23. CR at distant sites and
any response at local
site (n=210)
CT
+
RT= 54 Gy/36#
CT alone
Median survival-17 months v/s 11 months
Survival rate at 3 years-22% v/s 13%
Survival rate at 5 years-9% v/s 4%
26. Rationale
Frequent brain mets in SCLC
20 %- at diagnosis
80%- during the course of the disease
Once symptomatic- results have been poor.
27. Incidence of brain metastasis decreased by 25% at 3 years (58.6% v/s
33.3%)
5.4 % survival benefit with addition of PCI
28. PCI IN EXTENSIVE STAGE DISEASE
14.6 % v/s
40.4%
27.1% v/s 13.3%
at 1 yr
29. DOSE OF PCI
Limited stage
25 Gy/10#
24 Gy/8#
30Gy/15#
Extensive stage
25 Gy/10#
Shorter fractionation scheme of 20 Gy/5# can be
used.
Dose>30 Gy should be avoided due to high risk of
neurotoxicity
37. SUPERIOR VENA CAVA OBSTRUCTION
Symptomatic relief in
70-90% cases with
radiotherapy alone.
Dose- initial high dose
fractionation of 3- 4 Gy
followed by 1.8 Gy
fractionation
42. LS-SCLC
Concurrent CCT/RT
Early(1st or 2nd cycle)
Dose-45 Gy @1.5 Gy bd or 50-60 Gy @1.8 Gy once daily
Any response to chemo-PCI to a dose of 25 Gy/10#
ES-SCLC
Any response to chemo- PCI-25 Gy/10# or shorter 20 Gy/5#
can be used.
Possible value of local RT are the subject of ongoing
investigation.
Palliation
45. Santa air hostess se-aapki shakal meri biwi se milti
hai
Air hostess ne zordar thappad santa k muh pe
mara
Santa- Kamal hai, Aadat bhi milti hai
46. Very Touchy story:
"Husband forgot to wish her on his Wife's birthday.
He came home late at night from the office .....
His wife shouted: How would u feel if u dont see me
for next few days?
He couldnt believe his luck. He replied at once.''
Wowww.....That would be great..!''
Monday passed & he didn't see her.
Tuesday he didnt see her
.
.
& wednesday passed too
.
.
On Thursday the swelling was better & he could
see her from the corner of his left eye...
Notas do Editor
Contralateral SCF and contralateralhilar excluded from the limited study in many studies. s
A 1992 meta-analysis evaluated randomized trials in which more than 2,100 patients with limited-stage SCLC were randomized to receive either chemotherapy alone or in combination with chest irradiation.236 Patients given combined modality therapy had a 14% reduction in death rate and an absolute 5.4% improvement in 3-year survival compared with those who received chemotherapy alone. Both differences were highly significant in this meta-analysis.(pignon and warde)
25-217 days
We treated 231 patients withLS-SCLC. TRT consisted of 45 Gy over 3 weeks (1.5 Gytwice daily), and the patients were randomly assignedto receive either sequential or concurrent TRT. All patientsreceived four cycles of cisplatin plus etoposideevery 3 weeks (sequential arm) or 4 weeks (concurrentarm). TRT was begun on day 2 of the first cycle ofchemotherapy in the concurrent arm and after thefourth cycle in the sequential arm.Results: Concurrent radiotherapy yielded better survivalthan sequential radiotherapy (P .097 by logranktest). The median survival time was 19.7 monthsin the sequential arm versus 27.2 months in the concurrentarm. The 2-, 3-, and 5-year survival rates forpatients who received sequential radiotherapy were35.1%, 20.2%, and 18.3%, respectively, as opposed to54.4%, 29.8% and 23.7%, respectively, for the patientswho received concurrent radiotherapy. Hematologictoxicity was more severe in the concurrent arm. However,severe esophagitis was infrequent in both arms,occurring in 9% of the patients in the concurrent armand 4% in the sequential arm. Takada et al. (4) demonstrated that concurrent treatmentled to better outcomes than sequential. However, their studywas underpowered to demonstrate a survival benefit (114 patientsin each arm), but it did show a tendency for improvedsurvival (median 27 vs. 20 months; p < .10) with concurrenttreatment. The improved outcome was accompanied by a significantincrease in Grade 3 or greater leukopenia (85% vs.54%) (
This suggests that in the setting of combined-modality treatment, modest changes in treatment delivery can result in clinically significant changes in outcome.
investigators showed that a shorter interval between the first day of chemotherapy administration and the last day of RT was associated with improved survival (12), indicating that accelerated tumor repopulation plays an important role.